Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) will webcast its analyst briefing on Thursday, December 17. The event will begin at 8:30 am ET. The meeting will be briefing the company’s development program featuring presentations regarding multiple tumor types by external clinical investigators and members of management. Those unable to attend the event may listen to a webcast on the company’s website at www.onyx-pharm.com/view.cfm/32/Event-Calendar. The webcast will remain on the site until December 31, 2009.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing anticancer therapies. The Company’s product, Nexavar (sorafenib) tablets, being developed with the Company’s collaborator Bayer HealthCare Pharmaceuticals (Bayer), is approved by the United States Food and Drug Administration (FDA), for advanced kidney cancer and liver cancer. Nexavar is an orally available kinase and angiogenesis inhibitor and is one of a new class of anticancer treatments that target both cancer cell proliferation and tumor growth through the inhibition of key signaling pathways. As of December 31, 2008, Nexavar was approved in more than 70 countries for the treatment of advanced kidney cancer and in more than 60 countries for the treatment of liver cancer.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
